MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

Johnston, Stephen; Martin, Miguel; Di Leo, Angelo; Im, Seock-Ah; Awada, Ahmad; Forrester, Tammy; Frenzel, Martin; C. Hardebeck, Molly; Cox, Joanne; Barriga, Susana; Toi, Masakazu; Iwata, Hiroji; P. Goetz, Matthew

doi:10.1038/s41523-018-0097-z

Public

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

Shared by NobleBlocks on Jan 17, 2019 • 12:00 AM UTC

Authors:

Stephen Johnston

Miguel Martin

Angelo Di Leo

Abstract

Abstract At the MONARCH 3 interim analysis, abemaciclib plus a nonsteroidal aromatase inhibitor (AI) significantly improved progression-free survival (PFS) and objective response rate (ORR) with a tolerable safety profile as initial treatment for hormone receptor-positive (HR+), human epidermal grow...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!